Zacks: Analysts Anticipate ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.12 EPS

Wall Street brokerages expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to post earnings per share of ($0.12) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for ZIOPHARM Oncology’s earnings. The highest EPS estimate is ($0.09) and the lowest is ($0.14). ZIOPHARM Oncology reported earnings of ($0.09) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 33.3%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, May 9th.

According to Zacks, analysts expect that ZIOPHARM Oncology will report full year earnings of ($0.56) per share for the current year, with EPS estimates ranging from ($0.78) to ($0.43). For the next year, analysts expect that the company will post earnings of ($0.67) per share, with EPS estimates ranging from ($0.96) to ($0.45). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow ZIOPHARM Oncology.

A number of equities analysts have recently weighed in on the stock. Griffin Securities reaffirmed a “buy” rating and issued a $23.00 price target (up from $21.00) on shares of ZIOPHARM Oncology in a research note on Friday, February 10th. Zacks Investment Research downgraded shares of ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, April 6th. Finally, JPMorgan Chase & Co. reissued a “hold” rating on shares of ZIOPHARM Oncology in a research report on Thursday, January 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $10.15.

A number of institutional investors have recently bought and sold shares of the company. Creative Planning increased its position in ZIOPHARM Oncology by 289.3% in the first quarter. Creative Planning now owns 57,863 shares of the biotechnology company’s stock valued at $367,000 after buying an additional 43,000 shares during the last quarter. Highbridge Capital Management LLC acquired a new position in ZIOPHARM Oncology during the fourth quarter valued at approximately $164,000. Teachers Advisors LLC increased its position in ZIOPHARM Oncology by 1.9% in the fourth quarter. Teachers Advisors LLC now owns 198,508 shares of the biotechnology company’s stock valued at $1,062,000 after buying an additional 3,699 shares during the last quarter. Vident Investment Advisory LLC increased its position in ZIOPHARM Oncology by 5.8% in the fourth quarter. Vident Investment Advisory LLC now owns 114,980 shares of the biotechnology company’s stock valued at $615,000 after buying an additional 6,260 shares during the last quarter. Finally, Norges Bank acquired a new position in ZIOPHARM Oncology during the fourth quarter valued at approximately $5,556,000. 41.26% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This story was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another publication, it was stolen and republished in violation of United States and international trademark & copyright laws. The original version of this story can be accessed at https://sportsperspectives.com/2017/05/20/zacks-analysts-anticipate-ziopharm-oncology-inc-ziop-to-announce-0-12-eps-updated-updated-updated.html.

Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) traded up 0.28% during midday trading on Monday, hitting $7.10. The stock had a trading volume of 1,216,951 shares. ZIOPHARM Oncology has a 12-month low of $4.45 and a 12-month high of $8.86. The firm’s market cap is $927.94 million. The company’s 50-day moving average price is $6.47 and its 200-day moving average price is $6.16.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

5 Day Chart for NASDAQ:ZIOP

Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ZIOPHARM Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply